Agenda
DRAFT AGENDA
Saturday: Sept 30th
Meeting Registration: 08:00am-08:30am
Introduction & Meeting Objectives 08:45am
John Gribben
Session I: T-cell lymphoma 09:00am-10:30am
Chairs: Laurence de Leval & Francine Foss
- Genomic Profiling for Clinical Decision Making in TCL; Laurence de Leval
- Translational Discovery in PTCL; Giorgio Inghirami
- Epigenetic drugs in T-cell lymphoma; François Lemonnier
- Therapeutic options for the treatment of PTCLs (valemetostat); Francine Foss
- Recent advances in the treatment of cutaneous TCL; Steve Horwitz
Roundtable Discussion
Coffee Break 10:30am-10:50am
Session II: Evolving frontline immune-chemotherapy for MCL 10:50am-12:20pm
and the impact on survival outcomes
Chairs: Stephen Ansell & TBC
- Biological characteristics of high-risk MCL; Eric Hsi
- Frontline therapy of MCL – addition of novel agents; Anita Kumar
- Does autologous transplant still have a role in MCL; John Kuruvilla
- Do you need to treat young and old MCL patients differently? TBC
- Novel agents for relapsed MCL; Yucai Wang
- Where does CAR T-cell therapy fit into treatment of MCL(KTE-19); TBC
Roundtable Discussion: Remaining gaps and perspectives
Session III: KEYNOTE address 12:20pm-1:15pm
Chair & Introduction; Andreas Rosenwald
Keynote Speaker; Riccardo Dalla-Favera
Emerging role of super-enhancer hypermutation deregulating gene expression in DLBCL: pathogenetic and therapeutic implications
Roundtable Discussion
Lunch 1:15pm-2:15pm
Session IV: New pathogenetic mechanisms and therapeutic targets in DLBCL: 2:15pm-3:45pm
Chairs: Riccardo Dalla-Favera & Louis Staudt
- Molecular Genetics of Relapsed DLBCL: Insight into Mechanisms of Therapy Resistance; Madeleine R. Berendsen
- Molecular pathogenesis of germinal center-derived B cell lymphomas; Laura Pasqualucci
- Genomic profiling for clinical decision making in DLBCL; Louis Staudt
- Genomic alterations in DLBCL; new relevant pathways and potential therapeutic targets; Ken Young
- Prognostic and therapeutic value of somatic mutations in DLBCL; Marek Trneny
Roundtable Discussion
Coffee Break: 3:45pm-4:00pm
Session V: Novel Therapies I 4:00pm-5:45pm
Chairs: John Gribben & Laurie Sehn
- Novel drug development: an industry perspective; Simon Rule (Astra Zeneca
Industry Panel discussion
ADCs:
- POLARIX; Polatuzumab vedotin; Laurie Sehn
- Zilovertamab; Sven De Vos
- Loncastuximab Tesirine; Paolo Caimi
- Camidanlumab; Andrew Davies
- Brentuximab vedotin; David Straus
- Emerging ADCs with novel targets; Juan PabloAlderuccio
Panel Discussion
Day 1 Wrap up 5:45pm-6:00pm
Sunday: October 1st
Session VI: Expanding the CAR platform for NHL 08:30am-10:40am
Chairs: David Maloney & Jason Westin
- Tis-a-cel; Anna Sureda
- Axi-cel; Sattva Neelapu
- Liso-cel; Dave Maloney
- Expanding to T cell lymphomas; Laquisa Hill (CD5 and CD7 CAR-T)
Roundtable Discussion (15 min)
- Repeat CAR-T following failure of a first CD19 CAR-T- Does it work?; David Miklos
- CB-010: CD19 directed, PD-1 KO, alloCAR for R/R B-cell lymphomas; Mehdi Hamadani
- Expanding CAR T-cells as a second-line therapy for LBCL: A paradigm shift?; Jason Westin
(ZUMA-23 front line)
- Allogeneic CAR-T for NHL- fact or fantasy?; Tanya Siddiqi
Roundtable Discussion: CAR-T in the real-World Setting
Coffee Break 10:40am-10:55am
Session VII: Novel Therapies II 10:55am-12:25pm
Chairs: Laurie Sehn & TBC
BTK Inhibitors:
- Ibrutinib combinations; TBC
- Zanubrutinib; TBC
- Acalabrutinib; Marek Trneny
- Pirtobrutinib (Loxo-305); Michael Wang
- BTK Degraders – NX-2127; TBC
Menin Inhibitors:
- BMF-219; Jeffrey Lancet
Roundtable Discussion
Lunch 12:25pm-1:25pm
Session VIII: BiTEs for NHL 1:25pm-3:15pm
Chairs: Martin Hutchings & Marion Subklewe
- CD20/CD3 bispecific antibodies: How to choose? Mazyar Shadman
- Glofitamab; Martin Hutchings
- Mosunetuzumab; Nancy Bartlett
- Blinatumomab; Marion Subklewe
Roundtable Discussion
- Odronextamab;
- Plamotamab; Elisabeth Budde
- TNB 486; Ranjit Nair
- DuoBody-CD3xCD20 (Epcoritamab); Martin Hutchings
Roundtable Discussion
Final Meeting Summary & Conclusions: iwNHL Committee 3:15pm-3:20pm
